GHRP-2

Volume: 5 MG

Dosage: 5 MG/VIAL

Clinical dosing: 100 - 400 mcg/day

Description:

Peptide GHRP-2 (Growth Hormone Releasing Peptide-2; Pralmorelin) is a synthetic analogue of met-enkephalin (naturally occurring, endogenous opioid peptide) and growth hormone secretagogue (GHS), that acts as growth hormone secretagogue receptor (GHSR) agonist and stimulates natural production of growth hormone (GH). GHRP-2 is a single, non-glycosylated polypeptide chain containing 6 amino acids, with the amino acid sequence D-Ala-D-(β-naphthyl)-Ala-Ala-Trp-D-Phe-Lys-NH2 and molecular mass 817.9749 g/mol. This GHR peptide has been extensively studied for its utility as a growth hormone secretagogue (GHS). GHRP-2 was the first of this class of drugs to be introduced clinically. It is used as a diagnostic agent, which is sold in a single dose formulation for the assessment of growth hormone deficiency (GHD). In past, GHRP-2 was also under investigation for the treatment of GHD and short stature (pituitary dwarfism), and made it to phase II clinical trials for these indications. However, the ability of GHRP-2 to increase plasma GH levels in humans with GHD has been shown to be significantly lower compared to healthy individuals, therefore ultimately, GHRP-2 peptide as a GHD treatment has never been marketed.

Compound Specifications:

Originale product made in UK.